La actinomicosis es una infección oportunista crónica, granulomatosa, supurativa e infrecuente que, en estados de inmunosupresión, como el provocado tras el tratamiento con anticuerpos monoclonales anti-TNF, puede complicarse con cuadros clínicos más graves.

---

Bibliografía del caso clínico
1. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148-155, 2003.
2. Aleric I, Katalinic D, Vcev A, Brinar M. Pulmonary actinomycosis coexisting with intestinal tuberculosis as a complication of adalimumab treatment for Crohn's disease. ActaGastroenterolBelg 80(4):544-546, 2017.
3. Santos-Antunes J, Nunes AC, Macedo G. Mediterranean spotted fever in a patient with Crohn's disease under adalimumab: First case report and review of the literature. GastroenterolHepatol 38(6):379-380, 2015.
4. Ferrer Bradley I, Maroto Arce N, Mora Escrig M, Hinojosa Del Val J. Pulmonary aspergillosis in a Crohn's disease patient receiving adalimumab and steroid therapy. GastroenterolHepatol ;42(6):387-388, 2019.
5. Cohen RD, Bowie WR, Enns R, Flint J, Fitzgerald JM. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax 62(11):1013-1014, 2007.
6. Kim ES, Song GA, Cho KB, Park KS, Kim KO, Jang BI, et al. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol21(11):3308-3316, 2015.
7. Blanco Pérez JJ, Aranda Torres A, Pego Reigosa JM, Núñez Delgado M, Temes Montes E, Guerra Vales JL. Tuberculosis pulmonar en relación con adalimumab: estudio de 3 casos [Pulmonary tuberculosis associated to adalimumab: a study of 3 cases]. Arch Bronconeumol 46(4):203-205, 2010.
8. Moghimi M, Salentijn E, Debets-Ossenkop Y, Karagozoglu KH, Forouzanfar T. Treatment of cervicofacialactinomycosis: a report of 19 cases and review of literature. Med Oral Patol Oral Cir Bucal 18(4): e627-e632, 2013.
9. Boumaza A, Mezouar S, Bardou M, Raoult D, Mège JL, Desnues B. Tumor Necrosis Factor Inhibitors Exacerbate Whipple's Disease by Reprogramming Macrophage and Inducing Apoptosis. Front Immunol. 2021 May 20;12:667357. doi: 10.3389/fimmu.2021.667357. PMID: 34093562; PMCID: PMC8173622.
10. Cunha F, Sousa DL, Trindade L, Duque V. Disseminated cutaneous Actinomycesbovis infection in an immunocompromised host: case report and review of the literature. BMC Infect Dis. 2022 Mar 29;22(1):310. doi: 10.1186/s12879-022-07282-w. PMID: 35351021; PMCID: PMC8962608
11. CarboneJ, Perez-Rojas J,Farmiento E. Infectious pulmonarycomplications in patients treated with anti-TNF alpha monoclonal antibodiesand soluble TNFreceptor.Curr Infect Dis Rep 11:229-236, 2009.
12. Salavert M, Bastida G, Pemán J, Nos P. Coinfección oportunista durante el tratamiento con infliximab (antifactor de necrosis tumoral alfa) en un paciente con enfermedad de Crohn [Opportunisticco-infection in a patientwithCrohn'sdiseaseduringinfliximab (anti-TNFalpha) therapy]. Rev IberoamMicol 26(3):213-217, 2009.
13. Conrad A, Neven B, Mahlaoui N, et al. Infections in patients with chronic granulomatous disease treated with tumor necrosis factor alpha blockers for inflammatory complications. J ClinImmunol 41:185-193.

Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.